ALSO NOTED: Botox slowdown doesn't dampen Allergan's Q1; Shandong Lunan launches new API plant

> Allergan more than doubled first-quarter profits to $111 million as strong sales of its eye, skin, and nerve drugs offset lower domestic sales growth of its Botox cosmetic treatment. Report

> Shandong Lunan Pharmaceutical Group wrapped up construction of a new active ingredient plant focused on cephalosporin products, helping push China to the forefront of international 7-ADCA production volume. Report

> FDA asked ZymoGenetics to revise the press release on the launch of its first commercial product, saying that the announcement omitted important facts. Report

> FDA gave the nod to Eli Lilly's Strattera drug for maintenance treatment of ADHD in kids and adolescents. Report

> King Pharmaceuticals posted a year-over-year decline in first quarter revenues from $516 million to $432 million on generic competition for its blood pressure med Altace. Release

> Bentley Pharmaceuticals boosted first-quarter sales by 27 percent to $40 million, with net income of $1.1 million, or 5 cents per share. Release

> Celgene grew revenues by 57 percent in the first quarter, to $461 million, on a 96 percent hike in sales of its Revlimid cancer drug. Release

> Mylan got final FDA approval for its copycat form of the restless legs drug Requip, made by GlaxoSmithKline. Report

> IDM Pharma reported a net loss of $12.1 million on $2.4 million in first-quarter revenues. Report

> Enzon Pharmaceuticals has decided to spin off its biotech operations into a new company, adopting a suggestion floated by none other than Carl Icahn. Enzon report

> Wilex and GPC Biotech are preparing to merge, according to a prominent German newspaper. Report

> Novartis execs are discussing the company's plans in China. China report

And Finally... The first $271 million in facilities grant is just about ready to be doled out by the California stem cell institute. It will trigger more than three-quarters of a billion dollars worth of new construction for the laboratories that are being designed to develop stem cell therapies. Report

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.